We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
R&D
Northumbria Healthcare NHS Foundation Trust
ResearchAndDevelopment@northumbria-healthcare.nhs.uk
Dr
Victoria
Ferguson
victoria.ferguson@nhct.nhs.uk
R&D
Northumbria Healthcare NHS Foundation Trust
ResearchAndDevelopment@northumbria-healthcare.nhs.uk
Prof
Richard
Walker
richard.walker@nhct.nhs.uk
Jemma
Fenwick
jemma.fenwick@nihr.ac.uk
Extrapyramidal and movement disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Parkinson’s disease (PD) is a progressive, degenerative condition that affects movement. Subjective, handwriting examinations are commonly performed in the analysis of PD during clinical assessment. The Manus platform (developed by Manus Neurodynamica Ltd, Newcastle upon Tyne) is a novel sensor system that uses automated mathematical methods, integrated with a digital pen, that may assist with making a diagnosis in cases where a clear diagnosis cannot be made by a specialist physician. Sensors in the platform analyse movement of the pen, the hand and pen hand interaction during a series of simple drawing and writing tasks. Levels of performance in these tasks allow a diagnosis to be made. The overall objective of this project is assessing the usefulness of the novel system for differentiating between PD and other diagnoses, such as essential tremor within the ‘real world’ clinical setting. Current best practice for diagnosis of PD is expert clinical opinion or, in cases of doubt, DaTSCAN. DaTSCAN is expensive, requires specialist training to use and can be an unpleasant experience for patients.
Over two years, we will recruit 101 people, referred to NHS PD services in North East England, who are thought to have PD and who consent to participate. The study will be coordinated from Northumbria Healthcare NHS Foundation Trust. Assessment will be at one of the Trust's hospitals or at home if patients are unwilling or unable to travel. Those who do not have the capacity to consent due to cognitive impairment or other health problems will be excluded. If they consent, the spouses of those referred will also be assessed to provide further information on the system's accuracy. We will compare the diagnosis based on use of the platform to that obtained by current ‘best practice’. An accuracy of 90% sensitivity and 80% specificity is aimed for.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Unable to give fully informed consent for any reason. 2. Unable to hold the assessment pen for any reason. 3. Significant cognitive impairment based on Montreal Cognitive Assessment score 4. Presence of a pacemaker
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
R&D
Northumbria Healthcare NHS Foundation Trust
ResearchAndDevelopment@northumbria-healthcare.nhs.uk
R&D
Northumbria Healthcare NHS Foundation Trust
ResearchAndDevelopment@northumbria-healthcare.nhs.uk
Dr
Victoria
Ferguson
victoria.ferguson@nhct.nhs.uk
Jemma
Fenwick
jemma.fenwick@nihr.ac.uk
Prof
Richard
Walker
richard.walker@nhct.nhs.uk
The study is sponsored by NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST and funded by Innovate UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 16946
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
